Áttétes emlőrák: vizsgálatok itt: Szingapúr

8 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.

• 2. fázisTaking people
  ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

  Where

  Singapore

  Életkor

  18 év and over

  People

  120 worldwide

  Run by

  ALX Oncology Inc.

  See details and how to joinNCT07007559
• 3. fázisTaking people
  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  Where

  Singapore

  Életkor

  18 év and over

  People

  540 worldwide

  Run by

  Relay Therapeutics, Inc.

  See details and how to joinNCT06982521 · EU 2025-523083-21-00
• 3. fázisTaking people
  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  Where

  Singapore

  Életkor

  18 év and over

  People

  800 worldwide

  Run by

  Eli Lilly and Company

  See details and how to joinNCT07174336 · EU 2025-522791-92-00
• 1. fázisTaking people
  Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

  Where

  Singapore

  Életkor

  18 év and over

  People

  194 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT07604571
• 3. fázisTaking people
  Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  Where

  Singapore

  Életkor

  18 év and over

  People

  600 worldwide

  Run by

  LeonaBio

  See details and how to joinNCT05696626 · EU 2023-503708-10-00
• 3. fázisTaking people
  A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

  Where

  Singapore

  Életkor

  18 év and over

  People

  230 worldwide

  Run by

  Hoffmann-La Roche

  See details and how to joinNCT05894239 · EU 2022-502046-28-00
• 3. fázisTaking people
  A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  Where

  Singapore

  Életkor

  18 év and over

  People

  1200 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06312176 · EU 2023-504918-29-00
• 1/2. fázisTaking people
  Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

  Where

  Singapore

  Életkor

  18 év to 100 év

  People

  280 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT06726148 · EU 2024-517281-42-00